Lista de obras - Azucena Esparís-Ogando - Dominio Público Uruguay

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

artículo científico publicado en 2005

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

artículo científico publicado en 2012

Bortezomib is an efficient agent in plasma cell leukemias

artículo científico publicado en 2005

Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue.

artículo científico publicado en 2013

Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms

scientific article published on 01 April 1999

Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme

artículo científico publicado en 2000

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

artículo científico publicado en 2009

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

artículo científico publicado en 2013

Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis

artículo científico publicado en 2007

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2

artículo científico publicado en 2002

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target

scientific article published on 15 May 2009

Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.

artículo científico publicado en 2002

MEK5 promotes lung adenocarcinoma

artículo científico publicado en 2019

Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.

artículo científico publicado en 2002

Multifunctional role of Erk5 in multiple myeloma

artículo científico publicado en 2005

Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies

artículo científico publicado en 2016

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

scientific article published on 01 July 2007

Neuregulins and cancer.

artículo científico publicado en 2008

ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA.

artículo científico publicado en 2016

Potent antimyeloma activity of a novel ERK5/CDK inhibitor

artículo científico publicado en 2013

Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway

scientific article published on 04 March 2019

Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase

artículo científico publicado en 1999

Stimulation of cleavage of membrane proteins by calmodulin inhibitors

artículo científico publicado en 2000

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

artículo científico publicado en 2008

Targeting the EGF/HER Ligand-Receptor System in Cancer.

artículo científico publicado en 2016

The alpha-bungarotoxin receptor purified from a human neuroblastoma cell line: biochemical and immunological characterization

artículo científico publicado en 1989

The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.

artículo científico publicado en 2006

The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.

artículo científico publicado en 2014

The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation.

artículo científico publicado en 2008

The nicotinic receptors in the nervous system

artículo científico publicado en 1988

Therapeutic potential of ERK5 targeting in triple negative breast cancer

artículo científico publicado en 2014

Lista de obras de Azucena Esparís-Ogando

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

Bortezomib is an efficient agent in plasma cell leukemias

Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue.

Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms

Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target

Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.

MEK5 promotes lung adenocarcinoma

Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.

Multifunctional role of Erk5 in multiple myeloma

Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

Neuregulins and cancer.

ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA.

Potent antimyeloma activity of a novel ERK5/CDK inhibitor

Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway

Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase

Stimulation of cleavage of membrane proteins by calmodulin inhibitors

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

Targeting the EGF/HER Ligand-Receptor System in Cancer.

The alpha-bungarotoxin receptor purified from a human neuroblastoma cell line: biochemical and immunological characterization

The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.

The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.

The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation.

The nicotinic receptors in the nervous system

Therapeutic potential of ERK5 targeting in triple negative breast cancer